Qiagen (QGEN) & Puma Biotechnology (PBYI) Critical Comparison

Qiagen (NASDAQ: QGEN) and Puma Biotechnology (NASDAQ:PBYI) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider and Institutional Ownership

62.4% of Qiagen shares are held by institutional investors. Comparatively, 96.1% of Puma Biotechnology shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 21.1% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Qiagen and Puma Biotechnology, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen 0 7 5 0 2.42
Puma Biotechnology 0 1 8 0 2.89

Qiagen currently has a consensus price target of $33.36, indicating a potential upside of 4.08%. Puma Biotechnology has a consensus price target of $130.67, indicating a potential upside of 24.21%. Given Puma Biotechnology’s stronger consensus rating and higher possible upside, analysts clearly believe Puma Biotechnology is more favorable than Qiagen.

Profitability

This table compares Qiagen and Puma Biotechnology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Qiagen 6.40% 11.36% 6.37%
Puma Biotechnology N/A -208.58% -145.91%

Valuation & Earnings

This table compares Qiagen and Puma Biotechnology’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Qiagen $1.34 billion 5.45 $80.40 million $0.39 82.18
Puma Biotechnology N/A N/A -$276.01 million ($8.18) -12.86

Qiagen has higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Qiagen has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Summary

Qiagen beats Puma Biotechnology on 7 of the 12 factors compared between the two stocks.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company’s automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply